Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some label-consistent statements are present (approved indication, QID dosing, contact lens timing, blurred vision as common AE, contraindication for hypersensitivity). However, many detailed mechanistic/efficacy, population restriction, safety, and multiple non-label specifics (e.g., preservative-free, pregnancy category phrasing, pricing/insurance, specific trial-effect percentages/points, rebound/combination therapy/gland pathology claims, and risk statements like avoiding infections) are not supported or are contradicted by label excerpts provided.
Category Scores
Accurate Statements
Miebo (perfluorohexyloctane ophthalmic solution 100%) is FDA-approved for dry eye disease.
Label: 1 INDICATIONS AND USAGE states MIEBO is indicated for treatment of the signs and symptoms of dry eye disease (DED).
Miebo is dosed as 1 drop 4x daily in each eye.
Label: 2.1 Recommended Dosage states instill one drop four times daily into affected eye(s).
Miebo should not be administered while wearing contact lenses.
Label: 5.1 Use with Contact Lenses states MIEBO should not be administered while wearing contact lenses.
Common side effects include blurred vision in 5-10% of patients.
Label: 6.1 states the most common ocular adverse reaction was blurred vision; (the provided excerpt does not quantify as 5–10%).
Blurred vision is usually transient (as described).
No transient duration statement appears in provided excerpts.
Unsupported Statements
Miebo is indicated to treat the signs and symptoms of dry eye by targeting evaporative dry eye.
Mechanistic focus on 'targeting evaporative dry eye' is not stated in the provided indication excerpt; label mechanism states exact mechanism of action is not known.
Miebo forms a protective layer on the tear film to reduce evaporation.
Label supports reduction of evaporation via monolayer expectation, but provided excerpt does not use the phrase 'protective layer'; still broadly consistent, yet not explicitly stated in the provided label text as a 'protective layer.'
Miebo is preservative-free.
Preservative status is not provided in the supplied label excerpts.
Miebo does not alter aqueous tear production.
No statement regarding aqueous tear production appears in the supplied excerpts.
MGD is the leading cause of evaporative dry eye in the context described.
No epidemiology/causality statement appears in supplied label excerpts.
Miebo addresses evaporative dry eye indirectly by sealing the tear surface.
Label excerpt says forms a monolayer at the air-liquid interface expected to reduce evaporation; 'sealing' and 'indirectly' phrasing is not in provided label text.
Miebo uses a fluorinated hydrocarbon formula that mimics the oily layer and stabilizes tears regardless of underlying gland issues.
Not supported by provided label excerpts.
Miebo reduced tear evaporation by 69-71% at 4 weeks versus 14-19% with vehicle in Phase 3 trials (GOBLINA and MOJAVE).
Provided label excerpt does not mention tear evaporation percentage outcomes; also label names are GOBI and MOJAVE, not GOBLINA, and dose duration is described as 57 days, not '4 weeks' outcomes.
Miebo improved symptom scores (e.g., Eye Dryness Score) by 9.7-12.3 points versus 4.4-7.2 for vehicle.
Provided label excerpt states statistically significant reduction in VAS eye dryness score but does not provide these numerical values.
Ocular surface staining decreased significantly with Miebo in the described studies.
Supplied label excerpt does not mention ocular surface staining outcomes.
The Phase 3 trial results held in MGD-dominant subgroups.
Provided label excerpt does not mention MGD-dominant subgroups.
Miebo relieves evaporative dry eye driven by MGD without directly unclogging glands.
Not supported by provided label excerpts (including 'MGD' and 'unclogging glands' concepts).
Miebo does not cure gland atrophy or restore gland function long-term.
No such long-term gland-atrophy/gland function statements appear in provided label excerpts.
Miebo is preservative-free.
Not supported by provided label excerpts.
Miebo avoids rebound effects seen with some anti-inflammatories.
No statement about rebound effects appears in provided label excerpts.
No head-to-head trials compare Miebo directly to MGD-specific devices.
Not addressed in provided label excerpts.
Miebo does not fix underlying MGD pathology like gland loss.
Not supported by provided label excerpts.
Effectiveness varies among responders and non-responders.
Not addressed in provided label excerpts.
Responders show faster, sustained relief (as described).
Not addressed in provided label excerpts.
Non-responders may need combination therapy (as described).
Not addressed in provided label excerpts.
Blurred vision is usually transient (as described).
No transient description appears in provided label excerpts.
Miebo is not studied in severe MGD with significant atrophy.
No study population exclusions regarding 'severe MGD' appear in provided label excerpts.
Pregnancy category for Miebo is not established.
Provided label excerpt states 'no adequate and well controlled studies with MIEBO in pregnant women' but does not use 'pregnancy category' terminology.
Miebo should be avoided in active eye infections.
No infection/avoidance warning appears in provided label excerpts.
Miebo costs about $800-900 per 10 mL bottle (30-day supply) (as described).
Pricing is not included in the provided label excerpts.
Miebo is often covered by insurance for diagnosed dry eye (as described).
Insurance coverage statements are not included in the provided label excerpts.
Contradictions
Low
AI Statement
Common side effects include blurred vision in 5-10% of patients.
Label Reference
Label: 6.1 states blurred vision and conjunctival redness were reported in 1-3% of individuals.
Important Omissions
Hypersensitivity contraindication: avoid use in patients with a history of hypersensitivity reaction to perfluorohexyloctane.
Importance:
Moderate
Contact lens timing detail: remove prior to and for at least 30 minutes after administration (timing beyond the 'remove' instruction).
Importance:
Moderate
Exact label adverse reaction rate statement: blurred vision (and conjunctival redness) reported in 1-3% of individuals, rather than 5-10%.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Primary safety-relevant label elements were partially covered (contraindication topic not addressed; contact lens precaution partly addressed). Several unsupported or inaccurately quantified adverse reaction figures and multiple non-label warnings (e.g., 'avoid in active eye infections') could mislead risk perception.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many mechanistic/efficacy details, safety statements, and quantitative trial outcomes are not supported by the provided label excerpts; additionally, blurred vision incidence was misstated (5–10% vs 1–3%).
Suggested Improvement
Restrict claims to what the label excerpts support (indication, QID dosing, contact lens removal timing, hypersensitivity contraindication, and the provided adverse reaction rate range). Remove or qualify unsupported assertions about MGD, tear evaporation percentages/score point changes, infection avoidance, preservative status, pregnancy category phrasing, and non-label pricing/insurance.